Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Verisante Technology Inc. V.VRS


Primary Symbol: V.VER.H

Verisante Technology Inc is a Canada based medical device company. It is engaged in commercializing medical systems for the early detection of cancer. The products of the company are Verisante Aura which is for skin cancer detection and Verisante Core which is for lung, colon and cervical cancer detection. It utilizes a cancer detection platform while the operating software and probe technology. The group generates revenue from the sale and renting of its medical devices.


TSXV:VER.H - Post by User

Bullboard Posts
Comment by rhumpon Apr 09, 2012 2:41pm
264 Views
Post# 19772498

RE: full para

RE: full para

you are getting closer to the whole truth. Compare the AURA and Clinical practitioners biopsy ratios.  Why did MELA Sciences use a non-std statistical method on specificity???  Hmmmm???  Since the AURA is still a beta product, results will not be conclusive until more clinical studies can be done in a clinical setting. All in all, looks very promising.

AURA

Aura demonstrated specificities in these three tasks between 15% and 54% with GDA (in most instances using partial least squares resulted in higher specificities) - which resulted in a biopsy ratio (the number of non-melanoma lesions that undergo biopsy for each confirmed case of melanoma) of between 0.77:1 to 5.56:1.

MD's

Relative to the biopsy ratio, for reference the manuscript cites a retrospective study of ~5,000 pigmented skin lesions evaluated by ~500 general practitioners which resulted in a biopsy ratio between 58:1 and 21:1 (i.e. - 21 non-melanoma lesions biopsied for every confirmed case of melanoma).  Other unrelated studies have indicated biopsy ratios in clinical practice may be even significantly higher than these figures.  Although it's not necessarily fair (as there could be significant differences in the make-up of the various studies) to make a direct comparison of the biopsy ratios in the Aura study (which appear comparably very strong) with these other studies, at least on the face of it, the Aura data looks potentially persuasive. 

MELAFind

As we noted in our most recent update, the Aura data does look to be very compelling relative to clinical trial data from MELA Sciences Melafind device which showed a sensitivity of 98% and specificity of about 10% in the detection of melanoma.  Aura's biopsy ratio appears similarly relatively strong.  Also noteworthy is that MELA opted to use a statistical method different than either GDA or partial least squares, both of which are considered conservative.  As such, it's possible that Aura's specificities may have been relatively even stronger than Melafind's had the statistical methods used for both devices' studies been the same.

Bullboard Posts